AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04947150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Location-triggered notification
Description: If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF.
Study NCT04947150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflections on benefits of change
Description: Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
Study NCT04947150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach monitoring
Description: Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
Study NCT04947150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household support
Description: If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
Study NCT06641934 — intervention group
Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention
Study NCT06539260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Take 400 units of vitamin D3, twice daily, for a duration of 3 months.
Study NCT06539260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
Study NCT05536427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPM001
Description: IPM001 will be used against tumor cells
Study NCT04901975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
Study NCT05883800 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: On-couch adaptive radiotherapy
Description: A new treatment plan, guided by volumetric images, is created at each treatment session
Study NCT04822298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 160
Description: AMG 160 administered as an intravenous (IV) infusion
Study NCT04984356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-CART-007
Description: A single IV infusion of WU-CART-007 Cells on Day 1
Study NCT05638854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB002
Description: ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
Study NCT05638854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously as per schedule specified in the respective arm.
Study NCT05193942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Our Plan
Description: From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.
Study NCT05193942 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internation Informational Control
Description: From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
Study NCT06157892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)
Study NCT06157892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice daily by mouth (orally)
Study NCT04953156 — intervention group
Intervention type: DRUG
Intervention: Nitroglycerin
Description: data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion
Study NCT04953156 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.
Study NCT05186090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24-week resistance exercise program
Description: This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
Study NCT06518473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold.~Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)
Study NCT04597411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 225^Ac-PSMA-617
Description: administered intravenously under the dose escalation schedule
Study NCT04597411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68^Ga-PSMA-11
Description: administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
Study NCT05232136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: OH2: Oncolytic Type 2 Herpes Simplex Virus
Study NCT06314061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)
Description: A continuous glucose monitor which through a sensor in the skin registers glucose levels every 5 minutes. Glucose levels are shown by connecting the sensor to a mobile device or the Dexcom G7 Receiver where realtime alerts on deviating glucose levels will be sent.
Study NCT05711628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT05711628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and CT
Study NCT05711628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and CT
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05711628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05711628 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT05711628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT05711628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplant Conditioning
Description: Receive standard preparative chemotherapy regimen
Study NCT05711628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplant Conditioning
Description: Receive standard preparative chemotherapy regimen
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Given IV
Study NCT05711628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV
Study NCT04982380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live
Description: Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
Study NCT04982380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Siliankang simulating tablets
Description: Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
Study NCT06580951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Peripheral Nerve Interface
Description: The RPNI portion of the case will consist of blunt dissection of the cut sensory branches of the intercostal nerves at the T3 and/or T4 levels, with creation of a peripheral nerve interface using a small cuff of dissected pectoralis muscle and 3-0 Monocryl suture. The breast reconstruction will otherwise be performed as per standard protocol.
Study NCT04979390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316 administrated intravenously (IV) at protocol defined dose levels
Study NCT06629623 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04760444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Leader Diabetes Self-Management Support
Description: While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
Study NCT04760444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
Study NCT04760444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
Study NCT06464913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: With or without chest wall RT
Description: Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
Study NCT04934553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Training
Description: 12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
Study NCT04934553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral Therapy
Description: 12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
Study NCT06206681 — intervention group
Intervention type: PROCEDURE
Intervention: Ultra-pulsed Carbon Dioxide Laser
Description: Excision of eyelid lesion
Study NCT05169021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study NCT05169021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study NCT05169021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine+intensive antihypertensive therapy
Description: Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study NCT05169021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine+standard antihypertensive therapy
Description: Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study NCT05262556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101 (TQ Formula)
Description: Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
Study NCT05262556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (3mg/kg)
Description: Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
Study NCT05262556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1mg/kg)
Description: Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
Study NCT06382545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fanta (Pepsi gold) (FPG)
Description: endodontic treatment of posterior teeth with Fanta (Pepsi gold) (FPG)
Study NCT06382545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M3-pro+ Gold (assorted) (MPG)
Description: endodontic treatment of posterior teeth with M3-pro+ Gold (assorted) (MPG) rotary files.
Study NCT05142228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab-Aooe
Description: Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Study NCT05142228 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Study NCT05675631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension training
Description: This group will perform training using suspension devices.
Study NCT05675631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: This group will perform training using weights and elastic bands.
Study NCT06275880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration of PVP Collagen
Description: Intra-articular collagen injection plus physiotherapy program
Study NCT06275880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients who received conservative treatment through rehabilitation with a home program for one month
Study NCT06024499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HY209GEL Active
Description: Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
Study NCT06024499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo